Verinata v. Ariosa – compulsory license granted to Roche over prenatal screening technologies under eBay v. MercExchange

On July 19, 2018, the U.S. District Court, Northern District of California, denied a permanent injunction requested by Illumina, Inc, and instead ruled that a forward looking royalty for continued non-voluntary use of the invention, a type of compulsory license,… Continue Reading

Open letter supporting Italy’s proposed resolution on Improving the transparency of markets for drugs, vaccines and other health-related technologies

On March 6, 2019, 83 civil society organizations and 20 individuals asked delegates to the World Health Assembly (WHA) to support a proposed resolution on “Improving the transparency of markets for drugs, vaccines and other health-related technologies.” A copy of… Continue Reading

UNDP, Unitaid, and WHO caught in Big Pharma’s crosshairs

PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading

KEI asks NIST to extend comment period on their Special Publication 1234 Draft Green Paper on Return on Public Investment

Today KEI asked the Department of Commerce National Institute of Standards (NIST) to publish a notice in the Federal Register inviting comments on their Special Publication 1234, Draft Green Paper on Return on Public Investment, with an extended deadline. The… Continue Reading

Italy’s Draft WHO resolution: Improving the transparency of markets for drugs, vaccines and other health-related technologies

On 1 February 2019, Dr. Giulia Grillo, Italy’s Minister of Health, sent a letter to Dr. Tedros Adhanom Ghebreyesus, the Director General of the World Health Organization (WHO), with an attached “first draft” of a resolution on “Improving the transparency… Continue Reading